298 related articles for article (PubMed ID: 9338007)
21. Current progress in suicide gene therapy for cancer.
Yazawa K; Fisher WE; Brunicardi FC
World J Surg; 2002 Jul; 26(7):783-9. PubMed ID: 11948367
[TBL] [Abstract][Full Text] [Related]
22. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
[TBL] [Abstract][Full Text] [Related]
23. The genus Bifidobacterium for cancer gene therapy.
Fujimori M; Amano J; Taniguchi S
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):200-3. PubMed ID: 11926126
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
25. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Benouchan M; Do Nascimento F; Perret GY; Colombo BM
Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
[TBL] [Abstract][Full Text] [Related]
26. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.
Gadi VK; Alexander SD; Kudlow JE; Allan P; Parker WB; Sorscher EJ
Gene Ther; 2000 Oct; 7(20):1738-43. PubMed ID: 11083495
[TBL] [Abstract][Full Text] [Related]
27. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
[TBL] [Abstract][Full Text] [Related]
28. Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters.
Nuyts S; Theys J; Landuyt W; van Mellaert L; Lambin P; Anné J
Anticancer Res; 2001; 21(2A):857-61. PubMed ID: 11396175
[TBL] [Abstract][Full Text] [Related]
29. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
30. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
[TBL] [Abstract][Full Text] [Related]
31. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954.
de Poorter JJ; Tolboom TC; Rabelink MJ; Pieterman E; Hoeben RC; Nelissen RG; Huizinga TW
J Gene Med; 2005 Nov; 7(11):1421-8. PubMed ID: 15977303
[TBL] [Abstract][Full Text] [Related]
32. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway.
Cui W; Gusterson B; Clark AJ
Gene Ther; 1999 May; 6(5):764-70. PubMed ID: 10505099
[TBL] [Abstract][Full Text] [Related]
33. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
34. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Mar; 15(6):424-33. PubMed ID: 18079753
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapeutic tumour targeting using clostridial spores.
Minton NP; Mauchline ML; Lemmon MJ; Brehm JK; Fox M; Michael NP; Giaccia A; Brown JM
FEMS Microbiol Rev; 1995 Oct; 17(3):357-64. PubMed ID: 7576773
[TBL] [Abstract][Full Text] [Related]
36. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
[TBL] [Abstract][Full Text] [Related]
37. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Topf N; Worgall S; Hackett NR; Crystal RG
Gene Ther; 1998 Apr; 5(4):507-13. PubMed ID: 9614575
[TBL] [Abstract][Full Text] [Related]
38. Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.
Djeha HA; Todryk SM; Pelech S; Wrighton CJ; Irvine AS; Mountain A; Lipinski KS
Cancer Gene Ther; 2005 Jun; 12(6):560-71. PubMed ID: 15665820
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.
Mohr L; Shankara S; Yoon SK; Krohne TU; Geissler M; Roberts B; Blum HE; Wands JR
Hepatology; 2000 Mar; 31(3):606-14. PubMed ID: 10706550
[TBL] [Abstract][Full Text] [Related]
40. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
